细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2018.06.019

实用肿瘤学杂志 ›› 2018, Vol. 32 ›› Issue (6): 575-578.doi: 10.11904/j.issn.1002-3070.2018.06.019

• 综述 • 上一篇

细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展

刘娟综述, 张澍田审校

首都医科大学附属北京友谊医院消化内科, 国家消化系统疾病临床医学研究中心(北京 100050)

收稿日期:2018-07-05 出版日期:2018-12-28 发布日期:2018-12-27
通讯作者: 张澍田, E-mail:zhangshutian@ccmu.edu.cn
作者简介:刘娟, 女, (1989-), 硕士研究生, 从事消化系统早癌及癌前疾病分子机制的研究。

Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors

LIU Juan, ZHANG Shutian

Department of Gastroenterology, Beijing Friendship Hospital Affiliated to Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing 100050, China

Received:2018-07-05 Online:2018-12-28 Published:2018-12-27

摘要/Abstract

摘要： 细胞周期蛋白依赖性激酶抑制因子3(CDKN3)属于CDC14s家族的一种双特异性磷酸酶, 对肿瘤的早诊、治疗及预后判断有重要的临床意义, 但其在肿瘤发生发展中的作用机制目前尚未确定。本文通过对目前研究结果的回顾, 从细胞周期调控、细胞凋亡及侵袭迁移、CDKN3突变体及其亚细胞定位四个方面对CDKN3在肿瘤中作用机制的研究进展进行概述, 为明确下一步研究方向提供参考, 从而促进CDKN3临床转化应用, 提高肿瘤的临床诊治水平。

关键词: CDKN3, 细胞增殖, 肿瘤

Abstract: Cyclin-dependent kinase inhibitor 3(CDKN3)is a dual specificity phosphatase belonging to the CDC14s family.It has important clinical significance for early diagnosis, treatment and prognosis of tumors.The mechanism of CDKN3 in tumorigenesis and development has not yet been determined.Through reviewing the current research results, this paper summarizes the research progress of CDKN3 in tumors from four aspects:cell cycle regulation, apoptosis and migration & invasion, CDKN3 mutant and its subcellular localization.The direction provides a reference to promote the clinical transformation of CDKN3 and improve the clinical diagnosis and treatment of tumors.

Key words: CDKN3, Cell proliferation, Tumors

中图分类号:

刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.

LIU Juan, ZHANG Shutian. Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 575-578.

参考文献

1 Kenji T.Development of cell-cycle checkpoint therapy for solid tumors[J].Jpn J Clin Oncol, 2015, 45(12):1097-1102.
2 Otto T, Sicinski P.Cell cycle proteins as promising targets in cancer therapy[J].Nat Rev Cancer, 2017, 17(2):93-115.
3 Hannon GJ, Casso D, Beach D.KAP:A dual specificity phosphatase that interacts with cyclin-dependent kinases[J].Proc Natl Acad Sci U S A, 1994, 91(5):1731-1735.
4 Demetrick DJ, Matsumoto S, Hannon GJ, et al.Chromosomal mapping of the genes for the human cell cycle proteins cyclin C(CCNC), cyclin E(CCNE), p21(CDKN1)and KAP(CDKN3)[J].Cytogenet Cell Genet, 1995, 69(3/4):190-192.
5 Alonso A, Sasin J, Bottini N, et al.Protein tyrosine phosphatases in the human genome[J].Cell, 2004, 117(6):699-711.
6 Yu Y, Jiang X, Schoch BS, et al.Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma[J].Cancer Res, 2007, 67(1):130-138.
7 Li H, Jiang X, Yu Y, et al.KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway[J].Oncogene, 2015, 34(11):1432-1441.
8 Chen Q, Chen K, Guo G, et al.A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis[J].PLoS One, 2014, 9(10):e111611.
9 Niculescu MD, Yamamuro Y, Zeisel SH.Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene[J].J Neurochem, 2004, 89(5):1252-1259.
10 Xing C, Xie H, Zhou L, et al.Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation[J].Biochem Biophys Res Commun, 2012, 420(1):29-35.
11 Zang X, Chen M, Zhou Y, et al.Identifying CDKN3 gene expression as a prognostic biomarker in lung adenocarcinoma via meta-analysis[J].Cancer Inform, 2015, 14(Suppl 2):183-191.
12 Zhang LP, Li WJ, Zhu YF, et al.CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer[J].Int J Clin Exp Pathol, 2015, 8(5):4535-4544.
13 Barrón EV, Roman-Bassaure E, Sánchez-Sandoval AL, et al.CDKN3 mRNA as a biomarker for survival and therapeutic target in cervical cancer[J].PLoS One, 2015, 10(9):e0137397.
14 Li Y, Ji S, Fu LY, et al.Knockdown of cyclin-dependent kinase inhibitor 3 inhibits proliferation and invasion in human gastric cancer cells[J].Oncol Res, 2017, 25(5):721-731.
15 Lai MW, Chen TC, Pang ST, et al.Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells[J].Urol Oncol, 2012, 30(6):871-878.
16 Deng M, Wang J, Chen Y, et al.Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines[J].Mol Med Rep, 2016, 14(2):1523-1530.
17 Pita JM, Figueiredo IF, Moura MM, et al.Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas[J].J Clin Endocrinol Metab, 2014, 99(3):497-507.
18 Yu C, Cao H, He X, et al.Cyclin-dependent kinase inhibitor 3(CDKN3)plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling[J].Biomed Pharmacother, 2017, 96:1109-1118.
19 Berumen J, Espinosa AM, Medina I.Targeting CDKN3 in cervical cancer[J].Expert Opin Ther Targets, 2014, 18(10):1149-1162.
20 Dai W, Miao H, Fang S, et al.CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma[J].Mol Med Rep, 2016, 14(2):1509-1514.
21 Brown NR, Noble ME, Lawrie AM, et al.Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity[J].J Biol Chem, 1999, 274(13):8746-8756.
22 Nalepa G, Barnholtz-Sloan J, Enzor R, et al.The tumor suppressor CDKN3 controls mitosis[J].J Cell Biol, 2013, 201(7):997-1012.
23 Srinivas V, Kitagawa M, Wong J, et al.The tumor suppressor CDKN3 is required for maintaining the proper number of centrosomes by regulating the centrosomal stability of Mps1[J].Cell Rep, 2015, 13(8):1569-1577.
24 Yang C, Sun JJ.Mechanistic studies of cyclin-dependent kinase inhibitor 3(CDKN3)in colorectal cancer[J].Asian Pac J Cancer Prev, 2015, 16(3):965-970.
25 Liu D, Zhang J, Wu Y, et al.YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway[J].Int J Cancer, 2018, 142(7):1392-1404.
26 Yeh CT, Lu SC, Chen TC, et al.Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma[J].Cancer Res, 2000, 60(17):4697-4700.
27 Yeh CT, Lu SC, Chao CH, et al.Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant[J].Biochem Biophys Res Commun, 2003, 305(2):311-314.
28 Lin WR, Lai MW, Yeh CT.Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth[J].Oncol Rep, 2013, 29(3):903-910.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[4]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[5]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[6]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[7]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[8]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[9]	袁桂霞, 李岩, 冯婉琪, 夏小娟, 李旭. 抑癌基因DKK2抑制儿童肾母细胞瘤细胞增殖的机制研究[J]. 实用肿瘤学杂志, 2019, 33(1): 14-20.
[10]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[11]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[12]	卞秀森, 李光, 关欣宇, 张伊, 狄畅, 马璨. UHRF1通过调控细胞自噬抑制肺腺癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 498-502.
[13]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[14]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[15]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.

细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展

Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价